The outlook revision reflects Moody’s Investors Service’s expectation that Lifespan will continue to improve its financial performance over the next several years.
Moody’s also affirmed the “Baa2” rating on Lifespan’s $300 million of debt and its “Baa2” issuer rating.
The rating affirmation is based on a number of factors, including Lifespan’s large size, leading market share and role as a provider of unique medical care and teaching services in the state.
More articles on healthcare finance:
This week’s 5 must-reads for hospital CFOs
CMS projects next decade of health expenditures, enrollment: 5 things to know
Kno2’s cloud fax technology coming to Aprima customers
